<DOC>
	<DOCNO>NCT01464944</DOCNO>
	<brief_summary>This study address patient suffer acute febrile upper respiratory tract infection suspect viral origin . The purpose study determine antipyretic efficacy ( reduction fever lower body temperature raise state ) Aspirin dose 500 1000 mg ( study medication ) compare one Paracetamol dose 500 1000 mg ( comparator medication ) well one Placebo ( comparator medication without active substance ) . Despite common use fever treatment , scientific data adult support antipyretic efficacy Aspirin sparse . Therefore , purpose study collect data .</brief_summary>
	<brief_title>Placebo Active Controlled Study Compare Antipyretic Efficacy Aspirin® Patients With Acute Febrile Upper Respiratory Tract Infections Suspected Viral Origin</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Antipyretics</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Ambulatory male female patient 18 65 year age Acute uncomplicated febrile URTI suspect viral origin present 5 day Symptoms viral URTI Oral temperature &gt; /= 38.5 °C &lt; /= 40°C Patients physical finding consistent diagnosis pneumonia , otitis medium , bacterial sinusitis bacterial infection respiratory tract require antibiotic therapeutic intervention physician Current antibiotic treatment pretreatment antibiotic agent last week History presence asthma hypersensitivity ASA , salicylates , paracetamol , nonsteroidal antiinflammatory drug ; peptic ulceration gastric bleeding ; hemorrhagic diathesis ; hepatic and/or renal dysfunction ; Gilbert 's disease ; Quincke 's edema Any acute chronic disease opinion f investigator could interfere patient 's health wellbeing conduct study could interfere evaluation data generate subject Any condition possibly interfere gastrointestinal absorption study medication Pregnant lactate woman . All woman childbearing age undergo pregnancy test start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Upper Respiratory Tract Infections</keyword>
</DOC>